A team of Chinese scientists investigates metformin’s potential as an anti-aging intervention by examining its effects on cellular energy regulation and organ protection in both human cohorts and primate models. They report a 30% reduction in mortality before age 90 among postmenopausal women, and demonstrate metformin activates AMPK pathways to mitigate inflammation, protect vital tissues, and enhance metabolic resilience against age-related diseases.

Key points

• 30% reduction in mortality risk before age 90 among postmenopausal women in epidemiological analysis.
• Metformin activates AMPK to reduce inflammation and improve insulin sensitivity.
• Primate studies show organ protection and slowed brain aging via AMPK-driven gene activation.

Why it matters: By targeting aging processes rather than individual diseases, metformin offers a scalable strategy to prevent multiple age-related disorders and extend healthspan.

Investigators at the National Institute on Aging conduct extensive longitudinal and cross-sectional analyses of taurine in human, rhesus macaque, and mouse blood samples. Contrary to expectations, taurine levels remain stable or increase across age groups, undermining its decline as an aging biomarker and prompting a focus on individual variability for anti-aging interventions.

Key points

• Longitudinal and cross-sectional profiling of blood taurine in over 740 human participants across three cohorts, plus rhesus macaques and mice.
• Observation that taurine concentrations remain stable or increase with age, contradicting the hypothesized decline in aging.
• High inter-individual variability indicates genetic, dietary, and lifestyle factors overshadow age-related taurine changes.

Why it matters: These findings overturn the long-held belief that taurine decline marks aging, reshaping biomarker development and precision anti-aging therapies.

Nick Urban and Outliyr present a curated list of the ten best longevity podcasts, each offering deep dives into metabolic health, genetics, bioharmonizing, peptides, and functional medicine. With expert hosts like Peter Attia, Rhonda Patrick, and Dave Asprey, these shows deliver evidence-based strategies and practical tools to optimize your healthspan and performance span.

Key points

• Outliyr’s list surveys ten top longevity podcasts, highlighting host expertise, topics, and episode formats.
• The podcasts span core areas: metabolic health (The Drive), bioharmonizing frameworks (High Performance Longevity), and peptide interventions (LONGEVITY).
• Release frequency and episode duration metrics guide listeners in integrating content into regular learning routines.

Why it matters: Podcasts democratize cutting-edge longevity science, offering accessible insights and actionable strategies to extend healthspan.

Researchers at Beijing Tiantan Hospital employ a nested cross-validation radiomics pipeline with LASSO feature selection and TPOT-optimized random forest classifiers on contrast-enhanced T1-weighted MRI to noninvasively differentiate posterior pituitary tumors from pituitary neuroendocrine tumors and craniopharyngioma.

Key points

• Extracted 1510 radiomic features from contrast-enhanced T1-weighted MRI, including shape, first-order, GLCM, GLRLM, GLSZM, and GLDM metrics.
• Applied nested 10-fold cross-validation with LASSO-based dimensionality reduction and TPOT-optimized random forest classifiers to differentiate PPTs from NPPTs.
• Achieved 0.786 accuracy, 0.818 AUC, 0.778 specificity, and 0.788 sensitivity in an independent validation cohort.

Why it matters: Accurate noninvasive classification of pituitary tumors refines surgical planning, reduces intraoperative risks, and enhances patient outcomes.

ResearchAndMarkets.com publishes the “Artificial Intelligence in Pathology Market Report 2025,” detailing market expansion driven by increased funding, disease prevalence, AI-powered diagnostic tool integration and personalized medicine. The report forecasts growth from $1.39 billion in 2025 to $2.31 billion by 2029 at a 13.5% CAGR.

Key points

• Forecast market growth from $1.39 billion in 2025 to $2.31 billion by 2029 at a 13.5% CAGR.
• Integration of AI-powered diagnostic tools and EHR platforms streamlines clinical workflows and enhances accuracy.
• Deployment of CNNs, GANs and RNNs across applications like drug discovery, disease diagnosis, predictive analytics and training.

Why it matters: This report highlights AI’s transformative role in pathology, advancing diagnostic precision and personalized care through innovative algorithms and digital platforms.

Verified Market Research projects the AutoML sector to expand from $1.2 billion in 2024 at over 40 % CAGR through 2030, fueled by cloud integration, edge computing and cross-industry deployments.

Key points

• Global AutoML market valued at $1.2 billion in 2024, with 40 %+ CAGR expected through 2030
• North America leads adoption, followed by Europe and Asia-Pacific; emerging markets ramp up
• Cloud-native AutoML platforms drive scalability, while investments focus on explainability and bias mitigation

Why it matters: A rapidly growing AutoML market transforms AI adoption by lowering technical barriers, accelerating deployment, and unlocking new enterprise use cases across industries.